Urticaria is a type of skin disease characterized by rapid onset of hives (superficial dermis edema, erythema, pruritus, or burning sensation). According to whether the natural course exceeds 6 weeks, urticaria can be divided into acute and chronic urticaria (CU). At present, the evaluation of CU activity mainly depends on the Urticaria Activity Score (UAS), but the evaluation indicators are relatively single, and we need more reliable experimental data for evaluation. We typically summarize advanced biomarkers and several related pathogenic pathways discovered in recent years on urticaria, including the cell adhesion/chemotaxis pathway, interleukin (IL)-6/Janus tyrosine kinase/STAT pathway, IL-17/IL-23 pathway, basophil- and mast cell-related pathway, coagulation/fibrinolysis-related pathways, single-nucleotide polymorphism, and some other pathways. This review aims to find appropriate biomarkers so that we can evaluate disease activity, discover novel therapeutic targets, and predict the patients’ response more accurately to therapeutic agents.
Int Arch Allergy Immunol

中文翻译：

---

先进的生物标志物：荨麻疹的治疗和诊断目标

荨麻疹是一种以荨麻疹（浅表真皮水肿、红斑、瘙痒或烧灼感）为特征的皮肤病。根据自然病程是否超过6周，荨麻疹可分为急性和慢性荨麻疹（CU）。目前对CU活性的评价主要依靠荨麻疹活性评分（UAS），但评价指标相对单一，需要更可靠的实验数据进行评价。我们通常总结近年来发现的荨麻疹的先进生物标志物和几种相关的致病途径，包括细胞粘附/趋化途径、白细胞介素 (IL)-6/Janus 酪氨酸激酶/STAT 途径、IL-17/IL-23 途径、嗜碱性粒细胞-和肥大细胞相关通路、凝血/纤溶相关通路、单核苷酸多态性、以及其他一些途径。本综述旨在寻找合适的生物标志物，以便我们能够评估疾病活动度，发现新的治疗靶点，并更准确地预测患者对治疗药物的反应。
Int Arch 过敏免疫